Boehringer Ingelheim launches Frontline Flagship Store on Tmall

Ingelheim, Germany, 28 February 2019 – Boehringer Ingelheim announces that it has officially landed on Tmall¹ by opening its Frontline Flagship Store earlier this month. It is the first Tmall flagship store opened by a multinational animal health company for pet parasiticides. The flagship store specialises in selling Boehringer Ingelheim’s full range of pet parasiticides. It provides a reliable and convenient online purchasing channel for pet owners, while helping people to have better knowledge about raising pets, aiming to improve the health of pets and the pet owners’ families. This move also represents the company’s commitment to growing its business in China.

As the Boehringer Ingelheim’s official authorised e-commerce platform, the Tmall flagship store ensures product authenticity, selling the company’s popular full pet parasiticides portfolio: Frontline®, an ectoparaciticide for dogs and cats, Heartgard®, an endoparaciticide for dogs, Nexgard®, an ectoparaciticide for dogs, Nexgard® Spectra, an endectocide for dogs, as well as Broadline®, an endectocide for cats.

It marks another step Boehringer Ingelheim is taking in the field of e-commerce after establishing the Frontline Jingdong Self-operated Flagship Store on JD.com in April 2018. As a leader in pet parasiticides, the company is aware that that e-commerce is playing an increasingly important role among all sales channels for pet parasiticides. Boehringer Ingelheim is the first multinational animal health company to open a Tmall flagship store in the field of pet parasiticides

Boehringer Ingelheim will also leverage the Tmall flagship store to educate pet owners about pet health knowledge. The store provides online consultation service to answer questions from pet owners. It will also offer pet knowledge classes on a regular basis and provide privileged services for shop members.

Bradley Kaegi, Head of Pets Business China at Boehringer Ingelheim, shared: “Boehringer Ingelheim is a global leader in pet parasiticides segment and also an active promoter of online pet healthcare. We hope that we can better identify the needs of pet owners through the Tmall flagship store, while providing them with the best-quality pet products and services, so that we can further enhance our brand image. Together with our online presence on JD.com, we hope to encourage Boehringer Ingelheim’s online and offline customers to join us to embrace this unbounded retail era.”

¹Tmall.com is an open business-to-consumer platform enabling businesses to reach China’s consumer market.

Boehringer Ingelheim

Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success, rather than short-term profit. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.

Boehringer Ingelheim Animal Health Business Unit

Boehringer Ingelheim is the second largest animal health business in the world. We are committed to creating animal wellbeing through our large portfolio of advanced, preventive healthcare products and services. With net sales of 3.9 billion euros and around 10,000 employees worldwide, we are present in more than 150 markets. For more information visit: https://www.boehringer-ingelheim.com/animal-health/overview.

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany, and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.